Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center.

Shah, Rucha M; Sheikh, Sarah; Shah, Jimmy; Vivian, Elaina; Mejia, Alejandro; Shahin, Islam; Mantry, Parvez S

Shah, Rucha M; Sheikh, Sarah; Shah, Jimmy; Vivian, Elaina; Mejia, Alejandro; Shahin, Islam; Mantry, Parvez S.

Afiliación

Shah RM; Gastroenterology and Hepatology, Methodist Dallas Medical Center, Dallas, TX, USA.
Sheikh S; The Liver Institute, Methodist Dallas Medical Center, Dallas, TX, USA.
Shah J; Methodist Digestive Institute, Methodist Dallas Medical Center, Dallas, TX, USA.
Vivian E; The Liver Institute, Methodist Dallas Medical Center, Dallas, TX, USA.
Mejia A; The Liver Institute, Methodist Dallas Medical Center, Dallas, TX, USA.
Shahin I; Interventional Radiology, Methodist Dallas Medical Center, Dallas, TX, USA.
Mantry PS; The Liver Institute, Methodist Dallas Medical Center, Dallas, TX, USA.

J Gastrointest Oncol ; 12(4): 1718-1731, 2021 Aug.

Article en En | MEDLINE | ID: mdl-34532122

Palabras clave

Radioembolization; liver cancer; liver-directed therapy; locoregional treatment; selective internal radiation therapy (SIRT)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Año: 2021 Tipo del documento: Article